Researcher Accuses AstraZeneca PLC Of Manipulating Brilinta Data

Published: Feb 04, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

In July 2011, the Food and Drug Administration approved AstraZeneca AZN.LN -0.46% PLC's anticlotting drug Brilinta for patients with certain severe coronary conditions. A study had shown the pill saved lives and reduced heart attacks—a real eye-opener in medicine. But behind the scenes, a drama is unfolding over whether the drug should have been approved.

Help employers find you! Check out all the jobs and post your resume.

Back to news